-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that Novo Nordisk (NVO.US) CEO Mike Doestal said in an interview on Tuesday that the company must make more efforts to rebuild investor confidence because the Ozempic manufacturer's largest drug will face a patent cliff at the beginning of the next decade.

Zhitongcaijing·09/22/2026 09:17:12
Listen to the news
The Zhitong Finance App learned that Novo Nordisk (NVO.US) CEO Mike Doestal said in an interview on Tuesday that the company must make more efforts to rebuild investor confidence because the Ozempic manufacturer's largest drug will face a patent cliff at the beginning of the next decade.